Health News

Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side effect is so painful that many women halt their lifesaving medication. The findings appear in the online issue of Journal of Clinical Oncology…

Read more

Filed under: Women's Health
Tags: Arthritis, Breast Cancer, cancer, Drug, Genetic, Oncology, Online, Women's Health

Related posts

• Researchers find genetic variants that cause arthritis in breast cancer patients taking aromatase inhibitors (0)
  Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer. This serious side effect is so painful that many women halt their lifesaving medication. The findings appear today in the online issue of Journal of [...]
  
  
• Study Offers Hope For Women With ER-Negative Breast Cancer (0)
  Women who have estrogen (ER)-negative breast cancer may have more drug-treatment options than previously thought, a Creighton (pronounced Cray-ton) University study suggests. The study is reported in the Oct. 11 online version of the journal Oncogene... Read more [tags] Women's Health [/tags]
  
  
• Study Confirms Long-Lasting Benefit Of Trastuzumab (Herceptin) For Women With Early-Stage Breast Cancer (0)
  Women with an aggressive type of early-stage breast cancer (HER2-positive disease) given trastuzumab (Herceptin) for one year following standard chemotherapy are at significantly less risk of the cancer returning, and the effect is long lasting, according to the long-term results of the landmark HERA trial published Online First in The Lancet Oncology... Read more [tags] Women's Health [...]
  
  
• Study Confirms Long-Lasting Benefit Of Trastuzumab (Herceptin) For Women With Early-Stage Breast Cancer (0)
  Women with an aggressive type of early-stage breast cancer (HER2-positive disease) given trastuzumab (Herceptin) for one year following standard chemotherapy are at significantly less risk of the cancer returning, and the effect is long lasting, according to the long-term results of the landmark HERA trial published Online First in The Lancet Oncology... Read more [tags] Women's Health [...]
  
  
• FDA Approves New Test To Help Determine If Breast Cancer Patients Are Candidates For Herceptin Treatment (0)
  The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment. The test, called Inform Dual ISH, allows for measurement of the number of copies of the HER2 [...]